Altimmune (ALT) Capital Expenditures (2010 - 2026)

Altimmune (ALT) has 15 years of Capital Expenditures data on file, last reported at $21000.0 in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $21000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $22000.0 (changed N/A YoY), and the FY2025 annual result was $11000.0, changed N/A from the prior year.
• Capital Expenditures rose to $21000.0 in Q1 2026 per ALT's latest filing, from $1000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $60000.0 in Q3 2022 and troughed at -$4000.0 in Q2 2023.
• A 4-year average of $24375.0 and a median of $20000.0 in 2022 frame the typical range for Capital Expenditures.
• On a YoY basis, Capital Expenditures climbed as much as 466.67% in 2023 and fell as far as 121.05% in 2023.
• A 4-year view of Capital Expenditures shows it stood at $38000.0 in 2022, then tumbled by 110.53% to -$4000.0 in 2023, then surged by 125.0% to $1000.0 in 2025, then jumped by 2000.0% to $21000.0 in 2026.
• Business Quant data shows ALT's Capital Expenditures at $21000.0 in Q1 2026, $1000.0 in Q4 2025, and -$4000.0 in Q2 2023.